Uno studio di fase III su Dato-DXd con o senza durvalumab rispetto alla chemioterapia in combinazione con pembrolizumab scelta dallo sperimentatore in pazienti con carcinoma mammario triplo negativo PD-L1 positivo, recidivante localmente, inoperabile o metastatico
Uno studio randomizzato di Fase III, in aperto, su Datopotamab Deruxtecan (Dato-DXd) con o senza Durvalumab rispetto alla chemioterapia scelta dallo sperimentatore (Paclitaxel, Nab-paclitaxel o Gemcitabina + Carboplatino) in combinazione con Pembrolizumab in pazienti con PD-L1 positivo Cancro al seno triplo negativo localmente ricorrente, inoperabile o metastatico (TROPION-Breast05)
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The primary objective of the study is to demonstrate superiority of Dato-DXd + durvalumab relative to ICC + pembrolizumab by assessment of PFS as assessed by BICR in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
The study will be stratified based on geographic location (US/Canada/Europe vs. Dato-DXd monotherapy enrolling countries vs. rest of world), disease-free interval (DFI) history (de novo vs. prior DFI 6 to 12 months vs. prior DFI > 12 months), and prior PD-1/PD-L1 treatment for early stage TNBC (yes vs. no).
This study aims to see if Dato-DXd with durvalumab allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy and pembrolizumab. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: AstraZeneca Clinical Study Information Center
- Numero di telefono: 1-877-240-9479
- Email: information.center@astrazeneca.com
Backup dei contatti dello studio
- Nome: AstraZeneca Breast Cancer Study Locator Service
- Numero di telefono: +1-877-400-4656
- Email: az-bcsl@careboxhealth.com
Luoghi di studio
-
-
-
CABA, Argentina, 1425
- Reclutamento
- Research Site
-
CABA, Argentina, 1414
- Reclutamento
- Research Site
-
CABA, Argentina, C1425
- Ritirato
- Research Site
-
CABA, Argentina, C1113AAE
- Reclutamento
- Research Site
-
Ciudad Autónoma Buenos Aires, Argentina, C1430EFA
- Reclutamento
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1015ABO
- Reclutamento
- Research Site
-
Rosario, Argentina, 2000
- Reclutamento
- Research Site
-
San Nicolás de los Arroyos, Argentina, B2900
- Ritirato
- Research Site
-
-
-
-
-
Camperdown, Australia, 2050
- Reclutamento
- Research Site
-
Darlinghurst, Australia, 2010
- Completato
- Research Site
-
Heidelberg, Australia, 3084
- Completato
- Research Site
-
Melbourne, Australia, 3000
- Reclutamento
- Research Site
-
Nedlands, Australia, 6009
- Reclutamento
- Research Site
-
Waratah, Australia, 2298
- Ritirato
- Research Site
-
-
-
-
-
Barretos, Brasile, 14784-400
- Reclutamento
- Research Site
-
Curitiba, Brasile, 80730-150
- Reclutamento
- Research Site
-
Florianópolis, Brasile, 88034-000
- Reclutamento
- Research Site
-
Goiânia, Brasile, 74000-000
- Reclutamento
- Research Site
-
Itajaí, Brasile, 88301-220
- Reclutamento
- Research Site
-
Porto Alegre, Brasile, 90035-003
- Reclutamento
- Research Site
-
Recife, Brasile, 52010-075
- Reclutamento
- Research Site
-
São Paulo, Brasile, 01246-000
- Reclutamento
- Research Site
-
São Paulo, Brasile, 01317-001
- Reclutamento
- Research Site
-
Teresina, Brasile, 64049-200
- Reclutamento
- Research Site
-
-
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Reclutamento
- Research Site
-
Hamilton, Ontario, Canada, L8V 5C2
- Reclutamento
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Reclutamento
- Research Site
-
Montreal, Quebec, Canada, H4A 3J1
- Reclutamento
- Research Site
-
Montreal, Quebec, Canada, H2X 0A9
- Reclutamento
- Research Site
-
Québec, Quebec, Canada, G1S 4L8
- Reclutamento
- Research Site
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Reclutamento
- Research Site
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Reclutamento
- Research Site
-
-
-
-
-
Anyang, Cina, 455000
- Reclutamento
- Research Site
-
Beijing, Cina, 100044
- Reclutamento
- Research Site
-
Beijing, Cina, 100142
- Reclutamento
- Research Site
-
Bengbu, Cina, 233004
- Reclutamento
- Research Site
-
Changchun, Cina, 130021
- Reclutamento
- Research Site
-
Changsha, Cina, 410008
- Reclutamento
- Research Site
-
Changsha, Cina, 410013
- Reclutamento
- Research Site
-
Chengdu, Cina, 610000
- Reclutamento
- Research Site
-
Chengdu, Cina, 610041
- Reclutamento
- Research Site
-
Chongqing, Cina, 400030
- Ritirato
- Research Site
-
Fuzhou, Cina, 350014
- Reclutamento
- Research Site
-
Guangzhou, Cina, 510120
- Reclutamento
- Research Site
-
Guangzhou, Cina, 510060
- Reclutamento
- Research Site
-
Guangzhou, Cina, 510700
- Reclutamento
- Research Site
-
Hangzhou, Cina, 310009
- Reclutamento
- Research Site
-
Hangzhou, Cina, 310022
- Reclutamento
- Research Site
-
Hangzhou, Cina, 310016
- Reclutamento
- Research Site
-
Harbin, Cina, 150081
- Reclutamento
- Research Site
-
Hefei, Cina, 230031
- Reclutamento
- Research Site
-
Jinan, Cina, 250021
- Attivo, non reclutante
- Research Site
-
Meizhou, Cina, 514031
- Reclutamento
- Research Site
-
Nanchang, Cina, 330009
- Reclutamento
- Research Site
-
Nanjing, Cina, 210009
- Reclutamento
- Research Site
-
Nanjing, Cina, 2100008
- Reclutamento
- Research Site
-
Nanning, Cina, 530021
- Reclutamento
- Research Site
-
Shandong, Cina
- Reclutamento
- Research Site
-
Shanghai, Cina, 200025
- Reclutamento
- Research Site
-
Shanghai, Cina, 200080
- Completato
- Research Site
-
Shenyang, Cina, 110004
- Reclutamento
- Research Site
-
Taiyuan, Cina, 030000
- Reclutamento
- Research Site
-
Tianjin, Cina, 300000
- Reclutamento
- Research Site
-
Wenzhou, Cina, 325000
- Reclutamento
- Research Site
-
Wuhan, Cina, 430022
- Reclutamento
- Research Site
-
Wuhan, Cina, 430079
- Reclutamento
- Research Site
-
Xi'an, Cina, 710061
- Reclutamento
- Research Site
-
Xiamen, Cina, 361003
- Reclutamento
- Research Site
-
Xintai, Cina, 54031
- Reclutamento
- Research Site
-
Xuzhou, Cina, 221009
- Reclutamento
- Research Site
-
Zhanjiang, Cina, 524003
- Reclutamento
- Research Site
-
Zhengzhou, Cina, 450008
- Reclutamento
- Research Site
-
Zhengzhou, Cina, 450052
- Reclutamento
- Research Site
-
-
-
-
-
Busan, Corea del Sud, 49241
- Completato
- Research Site
-
Daegu, Corea del Sud, 41404
- Reclutamento
- Research Site
-
Goyang-si, Corea del Sud, 10408
- Reclutamento
- Research Site
-
Seongnam-si, Corea del Sud, 13620
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 03080
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 05505
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 03722
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 06591
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 02841
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 06273
- Reclutamento
- Research Site
-
-
-
-
-
Bacolod, Filippine, 6100
- Reclutamento
- Research Site
-
Cebu City, Filippine, 6000
- Reclutamento
- Research Site
-
City of Muntinlupa, Filippine, 1780
- Reclutamento
- Research Site
-
Manila, Filippine, 1000
- Reclutamento
- Research Site
-
Quezon City, Filippine, 1112
- Reclutamento
- Research Site
-
San Juan City, Filippine, 1502
- Reclutamento
- Research Site
-
-
-
-
-
Lille, Francia, 59000
- Reclutamento
- Research Site
-
Lyon, Francia, 69373
- Reclutamento
- Research Site
-
Montpellier, Francia, 34298
- Reclutamento
- Research Site
-
Paris, Francia, 75020
- Reclutamento
- Research Site
-
Saint-Herblain, Francia, 44805
- Reclutamento
- Research Site
-
Toulouse, Francia, 31059
- Reclutamento
- Research Site
-
Vandœuvre-lès-Nancy, Francia, 54511
- Reclutamento
- Research Site
-
Villejuif, Francia, 94800
- Reclutamento
- Research Site
-
-
-
-
-
Düsseldorf, Germania, 40479
- Ritirato
- Research Site
-
Essen, Germania, 45136
- Ritirato
- Research Site
-
Georgsmarienhütte, Germania, 49124
- Ritirato
- Research Site
-
Hamburg, Germania, 20357
- Ritirato
- Research Site
-
Hanover, Germania, 30625
- Ritirato
- Research Site
-
Heidelberg, Germania, 69120
- Ritirato
- Research Site
-
Heilbronn, Germania, 74078
- Ritirato
- Research Site
-
Leipzig, Germania, 04103
- Ritirato
- Research Site
-
-
-
-
-
Akashi-shi, Giappone, 673-8558
- Reclutamento
- Research Site
-
Bunkyō City, Giappone, 113-8431
- Reclutamento
- Research Site
-
Bunkyō City, Giappone, 113-8677
- Reclutamento
- Research Site
-
Chiba, Giappone, 260-8717
- Reclutamento
- Research Site
-
Chūōku, Giappone, 104-0045
- Reclutamento
- Research Site
-
Fukuoka, Giappone, 811-1395
- Reclutamento
- Research Site
-
Fukushima, Giappone, 960-1295
- Reclutamento
- Research Site
-
Gifu, Giappone, 501-1194
- Reclutamento
- Research Site
-
Hidaka-shi, Giappone, 350-1298
- Reclutamento
- Research Site
-
Hiroshima, Giappone, 734-8551
- Reclutamento
- Research Site
-
Hiroshima, Giappone, 730-8518
- Reclutamento
- Research Site
-
Isehara-shi, Giappone, 259-1193
- Reclutamento
- Research Site
-
Kamogawa-shi, Giappone, 296-8602
- Reclutamento
- Research Site
-
Kashiwa, Giappone, 277-8577
- Reclutamento
- Research Site
-
Kitaadachi-gun, Giappone, 362-0806
- Reclutamento
- Research Site
-
Kumamoto, Giappone, 860-8556
- Reclutamento
- Research Site
-
Kurume-shi, Giappone, 830-0011
- Reclutamento
- Research Site
-
Kōtoku, Giappone, 135-8550
- Reclutamento
- Research Site
-
Matsuyama, Giappone, 791-0280
- Reclutamento
- Research Site
-
Nagoya, Giappone, 466-8560
- Reclutamento
- Research Site
-
Nagoya, Giappone, 467-8602
- Reclutamento
- Research Site
-
Niigata, Giappone, 951-8566
- Reclutamento
- Research Site
-
Nishinomiya-shi, Giappone, 663-8501
- Reclutamento
- Research Site
-
Okayama, Giappone, 700-8558
- Reclutamento
- Research Site
-
Osaka, Giappone, 541-8567
- Reclutamento
- Research Site
-
Osakasayama-shi, Giappone, 589-8511
- Reclutamento
- Research Site
-
Ota-shi, Giappone, 373-8550
- Reclutamento
- Research Site
-
Sapporo, Giappone, 003-0804
- Reclutamento
- Research Site
-
Sendai, Giappone, 980-8574
- Reclutamento
- Research Site
-
Shinagawa-ku, Giappone, 142-8666
- Reclutamento
- Research Site
-
Shinjuku-ku, Giappone, 162-8655
- Reclutamento
- Research Site
-
Shinjuku-ku, Giappone, 160-0023
- Reclutamento
- Research Site
-
Tsu, Giappone, 514-8507
- Reclutamento
- Research Site
-
Tsukuba, Giappone, 305-8577
- Reclutamento
- Research Site
-
Yokohama, Giappone, 241-8515
- Reclutamento
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Reclutamento
- Research Site
-
-
-
-
-
Calicut, India, 673601
- Ritirato
- Research Site
-
Chennai, India, 600031
- Reclutamento
- Research Site
-
Jaipur, India, 302004
- Ritirato
- Research Site
-
Kochi, India, 682027
- Ritirato
- Research Site
-
Kolkata, India, 700160
- Ritirato
- Research Site
-
Kottayam, India, 686008
- Reclutamento
- Research Site
-
Marg Jaipur, India, 302004
- Reclutamento
- Research Site
-
Mohali, India, 160055
- Reclutamento
- Research Site
-
Mysuru, India, 570017
- Reclutamento
- Research Site
-
Nagpur, India, 440001
- Reclutamento
- Research Site
-
Nashik, India, 422009
- Reclutamento
- Research Site
-
New Delhi, India, 11029
- Reclutamento
- Research Site
-
New Delhi, India, 110075
- Reclutamento
- Research Site
-
Puducherry, India, 605006
- Reclutamento
- Research Site
-
Surat, India, 395002
- Reclutamento
- Research Site
-
Thiruvananthapuram, India, 695011
- Reclutamento
- Research Site
-
Vadodara, India, 391760
- Reclutamento
- Research Site
-
Visakhapatnam, India, 530053
- Ritirato
- Research Site
-
-
-
-
-
Bergamo, Italia, 24127
- Reclutamento
- Research Site
-
Empoli, Italia, 50053
- Reclutamento
- Research Site
-
Milan, Italia, 20132
- Reclutamento
- Research Site
-
Milan, Italia, 20141
- Reclutamento
- Research Site
-
Modena, Italia, 41124
- Ritirato
- Research Site
-
Naples, Italia, 80131
- Reclutamento
- Research Site
-
Padova, Italia, 35128
- Reclutamento
- Research Site
-
Reggio Emilia, Italia, 42123
- Reclutamento
- Research Site
-
Roma, Italia, 00168
- Reclutamento
- Research Site
-
Rozzano, Italia, 20089
- Reclutamento
- Research Site
-
-
-
-
-
CD Mexico, Messico, 04980
- Reclutamento
- Research Site
-
Guadalajara, Messico, 44670
- Ritirato
- Research Site
-
Guadalajara, Messico, 44638
- Reclutamento
- Research Site
-
Mexico City, Messico, 0 3100
- Reclutamento
- Research Site
-
Mexico City, Messico, 06760
- Reclutamento
- Research Site
-
México, Messico, 04700
- Reclutamento
- Research Site
-
Tuxtla Gutiérrez, Messico, 29090
- Reclutamento
- Research Site
-
-
-
-
-
Bialystok, Polonia, 15-027
- Ritirato
- Research Site
-
Bydgoszcz, Polonia, 85-796
- Ritirato
- Research Site
-
Gdansk, Polonia, 80-952
- Reclutamento
- Research Site
-
Gdynia, Polonia, 81-519
- Ritirato
- Research Site
-
Konin, Polonia, 62-500
- Ritirato
- Research Site
-
Krakow, Polonia, 31-501
- Reclutamento
- Research Site
-
Krakow, Polonia, 31-115
- Ritirato
- Research Site
-
Legnica, Polonia, 59-220
- Ritirato
- Research Site
-
Lodz, Polonia, 90-302
- Reclutamento
- Research Site
-
Lublin, Polonia, 20-090
- Ritirato
- Research Site
-
Przemyśl, Polonia, 37-700
- Ritirato
- Research Site
-
Warsaw, Polonia, 02-781
- Reclutamento
- Research Site
-
Wroclaw, Polonia, 53-413
- Ritirato
- Research Site
-
-
-
-
-
Cardiff, Regno Unito, CF14 2TL
- Reclutamento
- Research Site
-
Chelsea, Regno Unito, SW3 6JJ
- Reclutamento
- Research Site
-
Leicester, Regno Unito, Le5 4PW
- Reclutamento
- Research Site
-
Liverpool, Regno Unito, L7 8YA
- Terminato
- Research Site
-
London, Regno Unito, EC1A 7BE
- Reclutamento
- Research Site
-
London, Regno Unito, SW17 0QT
- Ritirato
- Research Site
-
Oxford, Regno Unito, OX3 7LE
- Sospeso
- Research Site
-
Surrey, Regno Unito, GU2 7XX
- Sospeso
- Research Site
-
Sutton, Regno Unito, SM2 5PT
- Reclutamento
- Research Site
-
Taunton, Regno Unito, TA1 5DA
- Reclutamento
- Research Site
-
-
-
-
-
Singapore, Singapore, 169610
- Reclutamento
- Research Site
-
Singapore, Singapore, 308433
- Reclutamento
- Research Site
-
Singapore, Singapore, 217562
- Reclutamento
- Research Site
-
Singapore, Singapore, 119228
- Ritirato
- Research Site
-
-
-
-
-
Barcelona, Spagna, 8035
- Reclutamento
- Research Site
-
Barcelona, Spagna, 08028
- Ritirato
- Research Site
-
Granada, Spagna, 18016
- Reclutamento
- Research Site
-
Hospitalet deLlobregat, Spagna, 08907
- Reclutamento
- Research Site
-
Madrid, Spagna, 28007
- Reclutamento
- Research Site
-
Madrid, Spagna, 28034
- Ritirato
- Research Site
-
Pamplona, Spagna, 31008
- Reclutamento
- Research Site
-
Santander, Spagna, 39008
- Reclutamento
- Research Site
-
-
-
-
Alabama
-
Daphne, Alabama, Stati Uniti, 36526
- Reclutamento
- Research Site
-
-
Arkansas
-
Springdale, Arkansas, Stati Uniti, 72762
- Reclutamento
- Research Site
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Ritirato
- Research Site
-
Fountain Valley, California, Stati Uniti, 92708
- Non ancora reclutamento
- Research Site
-
Glendale, California, Stati Uniti, 91204
- Reclutamento
- Research Site
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- Research Site
-
Santa Rosa, California, Stati Uniti, 95403
- Ritirato
- Research Site
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- Reclutamento
- Research Site
-
Denver, Colorado, Stati Uniti, 80210
- Non ancora reclutamento
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510
- Reclutamento
- Research Site
-
-
Florida
-
Altamonte Springs, Florida, Stati Uniti, 32701
- Non ancora reclutamento
- Research Site
-
Jacksonville, Florida, Stati Uniti, 32256
- Ritirato
- Research Site
-
Miami, Florida, Stati Uniti, 33176
- Reclutamento
- Research Site
-
Palm Bay, Florida, Stati Uniti, 32909
- Ritirato
- Research Site
-
Plantation, Florida, Stati Uniti, 33324
- Reclutamento
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30318
- Sospeso
- Research Site
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96819
- Ritirato
- Research Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- Research Site
-
Decatur, Illinois, Stati Uniti, 62526
- Ritirato
- Research Site
-
Elmhurst, Illinois, Stati Uniti, 60126
- Ritirato
- Research Site
-
Naperville, Illinois, Stati Uniti, 60540
- Ritirato
- Research Site
-
-
Indiana
-
New Albany, Indiana, Stati Uniti, 47150
- Ritirato
- Research Site
-
-
Iowa
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40503
- Ritirato
- Research Site
-
Louisville, Kentucky, Stati Uniti, 40202
- Ritirato
- Research Site
-
Louisville, Kentucky, Stati Uniti, 40207
- Ritirato
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Reclutamento
- Research Site
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Ritirato
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21215
- Ritirato
- Research Site
-
Columbia, Maryland, Stati Uniti, 21044
- Reclutamento
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Ritirato
- Research Site
-
Worcester, Massachusetts, Stati Uniti, 01655
- Ritirato
- Research Site
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Research Site
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Ritirato
- Research Site
-
-
Minnesota
-
Saint Paul, Minnesota, Stati Uniti, 55109
- Reclutamento
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Stati Uniti, 39401
- Ritirato
- Research Site
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63129
- Reclutamento
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87109
- Reclutamento
- Research Site
-
-
New York
-
Albany, New York, Stati Uniti, 12206
- Ritirato
- Research Site
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Research Site
-
Stony Brook, New York, Stati Uniti, 11794-7263
- Reclutamento
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- Reclutamento
- Research Site
-
Cincinnati, Ohio, Stati Uniti, 45245
- Reclutamento
- Research Site
-
Cleveland, Ohio, Stati Uniti, 44195
- Reclutamento
- Research Site
-
-
Pennsylvania
-
York, Pennsylvania, Stati Uniti, 17403
- Ritirato
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Reclutamento
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Reclutamento
- Research Site
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Research Site
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75246
- Reclutamento
- Research Site
-
Dallas, Texas, Stati Uniti, 75230
- Ritirato
- Research Site
-
Dallas, Texas, Stati Uniti, 75246
- Ritirato
- Research Site
-
El Paso, Texas, Stati Uniti, 79902
- Reclutamento
- Research Site
-
Flower Mound, Texas, Stati Uniti, 75028
- Ritirato
- Research Site
-
Fort Worth, Texas, Stati Uniti, 76104
- Ritirato
- Research Site
-
Houston, Texas, Stati Uniti, 77054
- Ritirato
- Research Site
-
Houston, Texas, Stati Uniti, 77090
- Ritirato
- Research Site
-
Houston, Texas, Stati Uniti, 77098
- Ritirato
- Research Site
-
Kingwood, Texas, Stati Uniti, 77339
- Ritirato
- Research Site
-
McKinney, Texas, Stati Uniti, 75071
- Ritirato
- Research Site
-
Sugar Land, Texas, Stati Uniti, 77479
- Reclutamento
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- Reclutamento
- Research Site
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Research Site
-
Midlothian, Virginia, Stati Uniti, 23114
- Reclutamento
- Research Site
-
Norfolk, Virginia, Stati Uniti, 23502
- Reclutamento
- Research Site
-
Roanoke, Virginia, Stati Uniti, 24014
- Reclutamento
- Research Site
-
-
Washington
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- Ritirato
- Research Site
-
-
-
-
-
Cape Town, Sud Africa, 7570
- Reclutamento
- Research Site
-
Johannesburg, Sud Africa, 2013
- Reclutamento
- Research Site
-
Johannesburg, Sud Africa, 2196
- Reclutamento
- Research Site
-
Johannesburg, Sud Africa, 2193
- Reclutamento
- Research Site
-
Paarl, Sud Africa, 7646
- Reclutamento
- Research Site
-
Pretoria, Sud Africa, 0081
- Reclutamento
- Research Site
-
Pretoria, Sud Africa, 0081
- Completato
- Research Site
-
-
-
-
-
Bangkok, Tailandia, 10210
- Reclutamento
- Research Site
-
Bangkok, Tailandia, 10400
- Reclutamento
- Research Site
-
Bangkok, Tailandia, 10330
- Reclutamento
- Research Site
-
Bangkok, Tailandia, 10700
- Reclutamento
- Research Site
-
Chiang Mai, Tailandia, 50200
- Reclutamento
- Research Site
-
Dusit, Tailandia, 10300
- Reclutamento
- Research Site
-
Khon Kaen, Tailandia, 40002
- Reclutamento
- Research Site
-
Songkhla, Tailandia, 90110
- Reclutamento
- Research Site
-
-
-
-
-
Hsinchu, Taiwan, 300
- Reclutamento
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Reclutamento
- Research Site
-
Taichung, Taiwan, 40447
- Reclutamento
- Research Site
-
Tainan, Taiwan, 704
- Reclutamento
- Research Site
-
Taipei, Taiwan, 100
- Reclutamento
- Research Site
-
Taipei, Taiwan, 112
- Reclutamento
- Research Site
-
Taipei, Taiwan, 10449
- Reclutamento
- Research Site
-
Taipei, Taiwan, 11259
- Reclutamento
- Research Site
-
Taoyuan, Taiwan, 333
- Reclutamento
- Research Site
-
-
-
-
-
Ankara, Turchia (Türkiye), 6200
- Reclutamento
- Research Site
-
Ankara, Turchia (Türkiye), 06520
- Reclutamento
- Research Site
-
Besevler Ankara, Turchia (Türkiye)
- Reclutamento
- Research Site
-
Istanbul, Turchia (Türkiye), 34010
- Reclutamento
- Research Site
-
Izmir, Turchia (Türkiye), 35575
- Ritirato
- Research Site
-
Küçükçekmece, Turchia (Türkiye), 34295
- Reclutamento
- Research Site
-
Samsun, Turchia (Türkiye), 55200
- Reclutamento
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Reclutamento
- Research Site
-
Hanoi, Vietnam, 100000
- Reclutamento
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Reclutamento
- Research Site
-
Huế, Vietnam, 530000
- Reclutamento
- Research Site
-
Hồ Chí Minh, Vietnam, 700000
- Reclutamento
- Research Site
-
Viet Tri, Vietnam, 35000
- Reclutamento
- Research Site
-
Vinh, Vietnam, 460000
- Reclutamento
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria
-
Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.
-
ECOG PS 0 or 1.
-
Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).
-
PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.
-
No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
- Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.
-
Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).
-
Measurable disease as per RECIST 1.1.
-
Adequate bone marrow reserve and organ function.
-
Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.
Key Exclusion Criteria
-
As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
-
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before Cycle 1 Day 1 and of low potential risk for recurrence.
-
Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
- Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
-
Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.
-
Active or uncontrolled hepatitis B or C virus infection.
-
Known HIV infection that is not well controlled.
-
Uncontrolled or significant cardiac disease.
-
History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
-
Clinically severe pulmonary function compromise.
-
Clinically significant corneal disease.
-
Active or prior documented autoimmune or inflammatory disorders.
-
Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.
-
Any concurrent anti-cancer treatment.
-
Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.
-
Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Dato-DXd + durvalumab
Arm 1: Dato-DXd + durvalumab |
Provided in 100mg vials. IV infusion. Experimental drug.
Altri nomi:
Provided in 500mg vials. IV infusion. Experimental drug.
Altri nomi:
|
|
Comparatore attivo: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab
Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) |
IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. |
|
Sperimentale: Dato-DXd
Arm 3: Dato-DXd |
Provided in 100mg vials. IV infusion. Experimental drug.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression Free Survival (PFS)
Lasso di tempo: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The comparison will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1 progression. However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits. The measure of interest is the HR of PFS. |
From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
OS is defined as the time from randomisation until the date of death due to any cause. |
From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
|
Objective Response Rate (ORR)
Lasso di tempo: From randomisation up until progression (anticipated to be up to 33 months).
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by the BICR/investigator assessment, per RECIST 1.1. |
From randomisation up until progression (anticipated to be up to 33 months).
|
|
Duration of Response (DoR)
Lasso di tempo: From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause. |
From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
|
Progression-Free Survival (PFS) by Investigator assessment
Lasso di tempo: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause. |
From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
|
Clinical Benefit Rate (CBR) at 24 weeks
Lasso di tempo: From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
CBR at 24 weeks is defined as the percentage of participants who have a CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/per investigator assessment and derived from the raw tumour data for at least 23 weeks after randomisation. |
From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
|
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Lasso di tempo: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in breast symptoms and arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Lasso di tempo: Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in pain as measured by the EORTC IL199. |
Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Lasso di tempo: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Lasso di tempo: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to First Subsequent Therapy (TFST)
Lasso di tempo: From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
TFST is defined as the time from randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause. |
From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Time to Second Subsequent Therapy (TSST)
Lasso di tempo: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
TSST is defined as the time from randomisation until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause. |
From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Progression Free Survival 2 (PFS2)
Lasso di tempo: From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
PFS2 will be defined as the time from the randomisation to the earliest progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice based on radiological or clinical progression. |
From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
|
Pharmacokinetics of Dato-DXd in combination with durvalumab
Lasso di tempo: From first dose to end of treatment (anticipated to be up to 33 months).
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload) in plasma. |
From first dose to end of treatment (anticipated to be up to 33 months).
|
|
Immunogenicity of Dato-DXd in combination with durvalumab
Lasso di tempo: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Presence of antidrug antibodies for Dato-DXd (confirmatory results: positive or negative, titres). |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
|
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
Lasso di tempo: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Safety and tolerability will be evaluated in the safety population in terms of AEs. |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie per sede
- Neoplasie
- Processi neoplastici
- Malattie della pelle
- Malattie del seno
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Neoplasie mammarie
- Metastasi neoplastica
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Complessi di coordinamento
- Taxoidi
- Ciclodecani
- Diterpenes
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Gemcitabina
- Carboplatino
- Paclitaxel
- pembrolizumab
- Durvalumab
- Paclitaxel diretto da 130 nm su albumina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D7630C00001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .